MRK
Merck & Co Inc
NEW YORK STOCK EXCHANGE, INC.· Pharmaceuticals· US· IPO 1941-01-01
$144.67
-3.69 (-2.49%)
last quote
Want the full multi-source brief on MRK?
The agent pulls regulatory filings, news flow, prediction-market pricing, and macro context — then synthesizes what's not yet in the price.
Today
Open
$144.67
High
$147.62
Low
$143.47
Previous close
$148.36
Fundamentals
Market cap
$366.03B
P/E (TTM)
115.36x
P/S (TTM)
5.50x
P/B
4.97x
Gross margin
77.28%
Operating margin
9.58%
Net margin
4.77%
Rev growth (YoY)
4.64%
EPS growth (YoY)
-80.70%
ROE
6.60%
52W high
$156.92
52W low
$82.01
Beta
0.12x
Industry peers
by market cap
Upcoming earnings
next 30 days
2027-02-02in 89 daysafter market
Q4 2026EPS est $1.80Rev est $16587.1M
Recent SEC filings
CIK 310158filing-language history →
Recent news
2026-10-28 → 2026-11-04
Yahoo · 14h
Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success
Even if the company's vaccine obtains approval, producing it at scale could be a big challenge.
ChartMill · 15h
Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declines
Sherwin-Williams, Home Depot and Merck led Dow Jones declines on Nov. 3, 2026, followed by Apple, Nike and Walmart, based on session price moves.
Yahoo · 15h
3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively
In 2022, the last time rates rose quickly, these stocks surged, a couple of them by more than 80%.
Yahoo · 16h
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial
Moderna surges on pre-earnings momentum, Pfizer dips after beating estimates and raising guidance, and Merck drops despite launching a new trial. When stock prices and headlines point in opposite directions across the sector, something beneath the surface deserves a closer look.
Yahoo · 17h
Pfizer Is Pitched for Its Dividend. The November 3 Report Has to Show Cash Flow Covers It
Key TakeawaysPfizer reports third-quarter results before the open on Tuesday, Nov. 3, as income pitches push its 5.
Yahoo · 17h
Merck’s Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.
Merck just posted its sixth straight earnings beat and its CEO is targeting $70 billion in mid-2030s revenue, yet the stock carries a looming patent cliff that could reshape everything. Whether the pipeline saves the story or the bears win depends on one upcoming FDA decision.
ChartMill · 17h
Dow Jones Biggest Decliners in Today's US Session
Today's US session Dow Jones decliners include Sherwin-Williams, Home Depot, Merck, Walmart and Apple, led by SHW down 3.2%.
Yahoo · 19h
Is Cancer And HIV Trial Wins Altering The Investment Case For Merck (MRK)?
Merck reported fresh Phase 3 wins in oncology and HIV, detailed progress on its personalized mRNA cancer vaccine with Moderna, secured new European approval for KEYTRUDA plus Padcev in bladder cancer, and raised full year 2026 sales guidance to US$66.8b to US$67.3b. Together with higher reported third quarter sales of US$18.1b and expanded late stage programs like sacituzumab tirumotecan, these up
This is the free preview
The agent layer adds regulatory-language drift detection, cross-venue prediction-market signals, macro overlays, programmable alert rules, overnight briefs, and a grounding verifier on every claim. 7-day Pro trial, no card required.
Start the trial